Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Cyprus: Dimercaprol; France: B.A.L; Greece: BAL; Hungary: Dicaptol; Italy: BAL; UK: Dimercaprol.

North America

Canada: BAL; USA: BAL.

Latin America

Brazil: Dimercaprol.


Japan: Bal.

Drug combinations


Dimercaprol: C~3~H~8~OS~2~. Mw: 124.23. (1) 1-Propanol, 2,3-dimercapto; (2) 2,3-Dimercapto-1-propanol. CAS-59-52-9.

Pharmacologic Category

Heavy Metal Antagonists. Antidotes. (ATC-Code: V03AB09).

Mechanism of action

Sulfhydryl group combines with ions of various heavy metals to form relatively stable, nontoxic, soluble chelates which are excreted in urine.

Therapeutic use

Antidote to gold, arsenic (except arsine), or acute mercury poisoning (except nonalkyl mercury). Adjunct to edetate calcium disodium in lead poisoning.

Pregnancy and lactiation implications

There are no adequate, well-controlled studies in pregnant women. Lead was found to cross the placenta in amounts related to maternal plasma levels. Possible outcomes of maternal lead exposure >10 μg/dL include spontaneous abortion, postnatal developmental delay, and reduced birth weight. Chelation therapy during pregnancy is for maternal benefit only and should be limited to the treatment of severe, symptomatic lead poisoning. It is not known if dimercaprol is excreted in breast milk, and therefore should be used with caution.

Unlabeled use


Hypersensitivity to dimercaprol or any component of the formulation. Hepatic insufficiency (unless due to arsenic poisoning). Iron, cadmium, or selenium poisoning.

Warnings and precautions

Potentially a nephrotoxic drug (use with caution in oliguria). Use with caution in G6PD deficiency (may increase risk of hemolytic anemia). Fevers may occur in children. Product contains peanut oil (use with caution in peanut allergy). Injections should be administered deeply I.M. at different sites.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart